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Abstract
Despite intense interest, methods that provide enhanced sensitivity and specificity in parallel measurements of candidate
protein biomarkers in numerous samples have been lacking. We present herein a multiplex proximity ligation assay with
readout via realtime PCR or DNA sequencing (ProteinSeq). We demonstrate improved sensitivity over conventional
sandwich assays for simultaneous analysis of sets of 35 proteins in 5 ml of blood plasma. Importantly, we observe a minimal
tendency to increased background with multiplexing, compared to a sandwich assay, suggesting that higher levels of
multiplexing are possible. We used ProteinSeq to analyze proteins in plasma samples from cardiovascular disease (CVD)
patient cohorts and matched controls. Three proteins, namely P-selectin, Cystatin-B and Kallikrein-6, were identified as
putative diagnostic biomarkers for CVD. The latter two have not been previously reported in the literature and their
potential roles must be validated in larger patient cohorts. We conclude that ProteinSeq is promising for screening large
numbers of proteins and samples while the technology can provide a much-needed platform for validation of diagnostic
markers in biobank samples and in clinical use.
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Introduction
Recent years have brought the opportunity to comprehensively
analyze genomes, epigenomes and transcriptomes through next
generation sequencing (NGS) [1]. However, analogous methods
have been lacking to measure large sets of proteins in biological
samples, while so far the search for clinically useful protein
biomarkers has met with limited success [2,3]. Greatly improved
analytical methods are therefore required in basic research and to
validate protein biomarkers by characterizing their distribution in
large series of patient samples, meeting stringent requirements for
sensitivity and specificity and with minimal consumption of
precious sample material. The aim is to find markers that can
help diagnose disease, preferably at early stages, and diagnose
responsiveness to specific therapies, or identify signs of relapse [4].
A number of approaches have been presented for protein
detection and quantitation in high-throughput. Mass-spectrometry
(MS) is combined with specific affinity reagents in methods such as
stable isotope standards and capture by anti-peptide antibodies
(SISCAPA) [5,6] and with multiple reaction monitoring (MRM)
[7]. Such assays demonstrate improved sensitivity over other MS-
based approaches but sample preparation is relatively time-
consuming and costly, and the degree of multiplexing is currently
limited.
Arrays of antibodies or other binding agents can be used to
capture proteins from biological samples for subsequent measure-
ment in assays that can be scaled to large numbers of analytes
[8,9,10]. A recent, interesting variant of this approach employs
large sets of high-affinity DNA aptamers for parallel capture of
proteins in biological samples, followed by detection and
quantitation [11,12].
Traditional sandwich immunoassays, which rely on dual-
recognition of target proteins by pairs of antibodies for capture
and signal reporting, offer an additional level of specificity over
single-binder assays. They can therefore in general provide
improved sensitivity of detection in complex biological specimens.
Such methods are robust and easy to use, and variants where
multiple proteins are detected in parallel are commercially
available. However, as the number of proteins investigated in
the same assay increases, risks for detection by non-cognate
antibody pairs grows rapidly, gradually undermining the added
specificity by dual recognition [13,14].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25583The proximity ligation assay (PLA) [15] is an immunoassay
where pairs of oligonucleotide-labeled antibodies - PLA probes -
are employed to detect an antigen of interest. When two PLA
probes bind the same antigen, the attached oligonucleotides are
brought in proximity, allowing these to be ligated upon addition of
a short complementary oligonucleotide. The ligated DNA strands
serve as reporter molecules that can be readily detected using
nucleic acid analysis techniques such as quantitative real-time
PCR (qPCR). The ligation and amplification steps provide
opportunities to constrain detection reactions so that only cognate
pairs of antibodies can give rise to detectable signals, thereby
avoiding cross-reactions. This property renders the assays highly
suitable for multiplexing. So far, multiplex solution-phase PLA
tests have been described for sets of 24 antigens simultaneously
[16,17,18].
We recently developed a solid-phase version of PLA (SP-PLA).
In this assay, an antibody immobilized on a solid support acts as a
capture reagent for localized enrichment of the antigen from a
complex mixture of proteins, such as serum or plasma [19]. After
washes, a pair of PLA probes is added followed by washes and
ligation of oligonucleotides brought in proximity. The solid
support allows washes to remove excess PLA probes and other
molecules that could interfere with detection of the protein of
interest. The unique requirement that each targeted protein is
recognized via three binding events in order to be recorded
provides exceptional specificity of detection compared to single-
binder or sandwich assays. This, in combination with the use of
PCR amplification to detect signals, allows for high specificity and
sensitivity of detection, and a broad dynamic range for protein
quantification.
Herein we report the development of multiplexed solid-phase
PLA coupled with NGS to digitally record patterns of protein
abundance in a method we call ProteinSeq. We demonstrate
simultaneous detection of 36 protein analytes, including one
internal control, in only 5 ml blood plasma samples. The digital
nature of NGS coupled with an exponentially increasing
sequencing capacity and rapidly decreasing sequencing cost
renders ProteinSeq promising for high-performance and high-
throughput biomarker validation in large clinical studies.
We used ProteinSeq to digitally record protein levels in plasma
samples from patients with CVD compared to normal controls,
revealing potentially important protein biomarkers.
Results
We have developed a scalable approach for sensitive, parallel
protein detection using minimal sample aliquots (Fig. 1). We first
established basic characteristics of the assay, before proceeding to
investigate plasma protein changes in samples from patients with
CVD.
A first requirement for high-throughput protein assays is the
ready access to suitable sets of reagents. Herein we used single
affinity-purified polyclonal antibody preparations, raised against
the whole or a large portion of the targeted proteins, as a source of
all three affinity reagents required for detection of any protein by
SP-PLA. Aliquots of the antibodies were immobilized on
paramagnetic microparticles or modified by covalent attachment
of oligonucleotides via their 59 or 39 ends. A rapid and convenient
protocol was developed for construction of up to 48 pairs of
antibody-oligonucleotide conjugates per 96-well plate within three
hours. The success rate of obtaining reagents for sensitive protein
detection using a commercial source of antibodies was a highly
satisfactory 90%, permitting construction of large reagent
repertoires.
To evaluate the specificity of multiplex SP-PLA, we first
assessed the tendency by each of the 36 different antibody sets to
detect any of the 36 targeted antigens in the panel. Individual
dilutions for every protein in the panel were prepared using
recombinant proteins and each one of the target proteins was
analyzed at high, medium or low concentrations (1 nM, 10 pM
and 0.1 pM, respectively in a total volume of 45 ul) using qPCR
for readout of PLA reaction products (Fig. 2a). For a conversion
of molar concentrations of each protein to protein concentrations
in pg/ml, please refer to Table S1. Unspecific signals were
classified as significant if they exceeded background levels by at
least two standard deviations. All but one of the instances where
unspecific signals were observed concerned proteins present at the
high concentration of 1 nM, a level substantially higher than the
blood level for these markers in both healthy and diseased
individuals. Furthermore, since the unspecific signals are not
reciprocal, i.e. the opposite combinations of reagents and target
molecules did not elicit unspecific signals, any contribution to
detection signals by cross-reactivity between analytes can be
estimated and accounted for.
In order to avoid risks of detection reactions involving non-
cognate PLA probe pairs, that is antibodies that are not
expected to bind the same protein, the assays were designed so
that only correct pairs of oligonucleotide-modified antibodies
could be joined by ligation (see Methods and Fig. S1). We
thus expected that background signals would show a lesser
tendency to increase as more sets of antibodies are used
compared to the situation for sandwich immunoassays. To
investigate this we measured background signals in individual
PLA tests compared to multiplex PLA, and we used the same
polyclonal antibodies in conventional sandwich immunoassays
performed singly or in multiplex in a bead-based system
(Luminex). The results, summarized in Figure 2b establish
that background signals from PLA do not increase significantly
when going from individual to multiplex tests. In contrast, using
the conventional sandwich immunoassay design background
signals increased greatly but variably as the number of detection
reagents was increased, as has been noted by others
[20,21,22,23]. Accordingly PLA is promising for higher degrees
of multiplexing than what can be achieved using conventional
sandwich immunoassays.
Next we compared multiplex SP-PLA with qPCR readout and
sandwich immunoassays with respect to assay sensitivity (lower
limit of detection, LOD) and the concentration range over which
proteins could be quantified (dynamic range) using the same
antibody preparations. Multiplex SP-PLA exhibited an average
overall improved sensitivity of 40-fold compared to sandwich
assays (Fig. 2c and Figure S2). Among 35 proteins, multiplex
SP-PLA had lower LOD for 27 analytes, while the sandwich
immunoassay was slightly more sensitive for the remaining eight,
perhaps because of a limited epitope range for these antisera.
Multiplex SP-PLA had a median dynamic range of five orders of
magnitude for the 35 targeted proteins, compared to three orders
of magnitude for the sandwich immunoassays. A list of detection
limits for each antigen for both multiplex SP-PLA and sandwich
assays can be found in Table S2.
We specifically evaluated the correlation between data obtained
by multiplex SP-PLA with qPCR readout and sandwich
immunoassays on a set of 46 plasma samples for six proteins,
namely E-selectin/CD62E, Fas-Ligand/TNFSF6, CCL16/HCC-
4, CXCL8/IL8, GDF-15 and Kallikrein-3/PSA. The median
Pearson correlation coefficient in these experiments was 0.70
(min=0.52, max=0.87) across all samples. The levels of all 35
proteins investigated by multiplex SP-PLA on two separate
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correlation coefficient of 0.75 (min=0.05, max=0.96).
The measurement of proteins via multiplex SP-PLA and qPCR
provides an analogue record of the protein complement in the
investigated samples. By contrast, NGS offers a means to digitally
record PLA-products that represent protein profiles in blood
samples to ultimately improve precision and sample throughput by
a procedure we call ProteinSeq.
To optimize detection of proteins over broad ranges of
abundance and avoid overrepresentation of PLA products
representing more abundant proteins we found that we could
adjust the detection efficiency. For proteins expressed at high levels
we could predictably lower the reporting rate by decreasing the
concentration of the corresponding PLA probes (see Methods
and Table S3).
We developed a protocol that significantly simplified prepara-
tion of sequencing libraries for PLA ligation products compared to
commercially available procedures (Fig. S3). Using this protocol,
amplified ligation products from different patient samples were
labeled with a set of twelve indexes, allowing us to analyze 96
patient or control samples in the eight lanes of an Illumina
Genome Analyzer IIx.
We applied ProteinSeq to investigate biobank plasma samples
from a group of CVD patients (n=63) and matched healthy
controls (n=19). Each sequenced product was assigned to a
plasma sample using the index sequences. Of the total reads, 92%
contained a recognizable index, allowing up to one mismatch. The
identity of the detected protein was inferred from two specific tag
sequences contributed by the two oligonucleotides used in the PLA
probes. From those reads that contained a recognizable index,
77.9% mapped uniquely to a reference sequence. The reference
sequence contained all possible ligation products and not just the
expected pairs of sequence tags, while allowing for up to five
mismatches. Out of all the uniquely mapped reads, as little as
1.5% involved incorrect probe pairs (see Fig. S4). This
demonstrates that the constrained ligation efficiently suppresses
unspecific signals originating from recognition of proteins by non-
cognate pairs of antibodies, supporting the notion that further
multiplexing should be possible.
The quantitative precision of measurement by sequencing was
marginally better than for qPCR (CV 22% vs. 29% averaged for
all proteins). In addition, we used data obtained from one patient
sample for which we acquired replicate measurements to establish
that correlation between replicate measurements for sequencing
and qPCR was similar for the two methods (Fig. 2d).
A multivariate classification method, introduced here for the
first time, was used for the analysis of the multidimensional data
generated by ProteinSeq. Prior to analysis two patient samples
containing missing values were removed from the original set of 63
patient samples, resulting in a total of 61 patient and 19 control
samples. The classifications resulted in an average false positive
rate estimate of 19% and an average negative rate estimate of 4%
for the novel projection method. These estimates are based on
5000 different designs using 48 patient examples plus 15 control
examples (80% of all the data) each time. Each design was then
tested using an external set of test examples consisting of 13
patients and 4 controls, from which the estimates were calculated.
Figure 3a illustrates the result of one of the 5000 different classifier
designs performed and evaluated. These findings were validated
by two commonly employed classification methods, namely
nearest shrunken centroid (NSC) and random forest (RF). For
further details on the novel projection method as well as the
comparison with the two established classification methods please
refer to the Methods and Material S1.
To identify the most promising potential biomarkers among
proteins included in our panel, we performed a 3-nearest neighbor
classification for each protein individually (Fig. 3b). Cystatin-B
stood out as the most informative protein for discriminating
patients and controls. This protein resulted in a false positive rate
of 28% and a false negative rate of only 2%. Both rates were
estimated as averages over 1000 repeated external 5-fold cross
validations. Kallikrein-6 and P-selectin both came second as
informative markers with an estimated false positive rate of
approximately 43% and false negative rate of 8%. Of these three
proteins, P-selectin has previously been identified as a promising
biomarker for CVD [24,25] but no reports were found on
Cystatin-B and Kallikrein-6, motivating further analyses of these
biomarkers in larger numbers of samples.
Discussion
We report herein the development and application of a
technology for highly specific and parallel protein measurements
with readout via DNA sequencing – ProteinSeq – suitable for
sensitive validation of biomarker candidates in plasma samples.
The use of a solid support along with the requirement for three
binding events to generate a detection signal ensures specificity of
detection, while low nonspecific ligation and efficient PCR
amplification of ligation products contribute to the sensitivity of
ProteinSeq analyses. The recognition events per target by three
antibodies also provides an opportunity to characterize more
challenging targets, such as complexes of interacting proteins or
proteins having undergone post-translational modifications
[26,27]. The requirement for target binding by three antibodies
could prove disadvantageous if the protein size imposes a
limitation of the number of available epitopes. However, we have
not observed any correlation between assay performance and
protein size for the 36 proteins included in our panel. Indeed,
some of the best performing assays in the panel are against
relatively small proteins such as interleukin-7 with a mass of
approximately 17 kilodalton. The use of polyclonal antibodies,
while convenient, fails to ensure that individual proteins are bound
by antibodies having the required combination of oligonucleotides.
Work is in progress to rapidly characterize optimal trios of clonal
affinity reagents (monoclonal antibodies or recombinant binders)
for solid-phase PLA tests.
We demonstrate the potential of the method for extensive
biobank analyses by simultaneously investigating 35 analytes in
5 ml aliquots of blood plasma with both minimal cross-reactivity
and improved limits of detection compared to traditional sandwich
immunoassays. This suggests that it will be possible to extend the
method for parallel analyses of much larger numbers of proteins.
Finally, we illustrate herein for the first time the use of NGS as a
readout through ProteinSeq, allowing digital protein measurement
in plasma samples.
Figure 1. Principle of multiplex SP-PLA. Pools of microparticles, each coated with one of the antibodies, are mixed with the sample (I). After
washes, pairs of PLA probes directed against each of the proteins are incubated with the microparticles (II), followed by washes and ligation of the
attached DNA strands (III). Ligated molecules are first amplified with primers directed against sequences present on all ligated DNA molecules (IV).
This universal pre-amplification is then followed by preparation of the reporter strands for next generation sequencing, or for qPCR (V). Subsequently
the abundance of each protein is calculated and multivariable classification of cases and controls is performed (VI).
doi:10.1371/journal.pone.0025583.g001
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same sample without a need to divide analyses in separate panels
based on the relative abundance of the target proteins in blood.
The use of single polyclonal antibody preparations to construct all
three classes of reagents needed for detection of each protein
avoids the need to identify suitable combinations of monoclonal
antibodies, thus overriding one of the important limitations for
analysis of large sets of proteins.
ProteinSeq lends itself for much higher level of multiplexing
than conventional sandwich immunoassays. This is supported by
Figure 2. a) Cross-reactivity table. The figure reflects the signals obtained when each protein in the panel was incubated individually with all PLA
probes of the panel. Correct signals are indicated along the diagonal. The colors indicate the protein concentration required to elicit detection signals
significantly exceeding the background. Recombinant proteins at known concentrations were used for the purpose of this experiment. b) Change in
background signals as a result of multiplexing. The background signals were measured for every antibody when incubated individually or in
combination with all other antibodies of the panel for multiplex SP-PLA and sandwich immunoassays. The y-axis shows the increase of background
when moving from individual to multiplex reactions. c) Limit of detection comparison between multiplex SP-PLA and sandwich
immunoassay. The log10 fold change in LOD between multiplex SP-PLA and sandwich immunoassay. d) Correlation between results of
sequencing and qPCR. Correlation between two replicated measurements of the same blood sample by qPCR (upper left), by sequencing (lower
right), and between measurement by realtime PCR and sequencing (upper right). The axes represent numbers of starting DNA amplicons for PCR
measurements and normalized numbers of reads for sequencing.
doi:10.1371/journal.pone.0025583.g002
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different between individual and multiplex assays, suggesting that
far greater multiplexing should be possible. By contrast, we
observed increased background with multiplexing of a conven-
tional sandwich immunoassay.
We demonstrated the potential of ProteinSeq for biomarker
validation in a study involving patients with coronary disease. In
the CVD sample set three proteins stood out as promising markers
in the univariate analysis, namely Cystatin-B, Kallikrein-6 and P-
selectin. P-selectin has been previously suggested as a promising
biomarker for CVD [24,25] but no reports were found on
Cystatin-B and Kallikrein-6, indicating that these might represent
novel biomarkers. Given that the number of samples used herein is
relatively small the potential of Cystatin-B and Kallikrein-6 should
be further and thoroughly investigated. Such a study would
require analyses of large numbers of samples within a reasonable
time frame, whereas for the identification of further biomarkers,
large numbers of proteins would have to be analyzed as well.
In this context DNA sequencing allows for specific, sensitive and
precise quantitation of ProteinSeq ligation products, providing
very high levels of sample and marker throughput. Digital protein
expression data can greatly augment analytical performance, and
the cost for such analyses will diminish rapidly, as the cost of DNA
sequencing is decreasing at a very rapid rate [28]. By optimally
encoding the identities of proteins and samples, only a small
number of nucleotides need be sequenced for unambiguous
identification and as shown herein little sample preparation is
required before PLA products are sequenced. We also demon-
strate, that reporting of proteins from different abundance classes
can be conveniently compressed with minimal loss of precision to
avoid excessive sampling of products for abundant proteins.
In conclusion, ProteinSeq provides opportunities for highly
multiplexed assays of proteins or protein variants in minimal
sample aliquots. It can thus allow validation of protein expression
patterns in biobank samples and in prospective studies, and the
method can provide a platform for clinical use.
Materials and Methods
Recombinant proteins and antibodies
All recombinant human proteins and all antibodies, with the
exception of IgG from mouse serum, were from R&D Systems.
The IgG from mouse serum was purchased from Sigma-Aldrich.
Both unbiotinylated and biotinylated affinity-purified forms of the
antibodies were used. All antibodies were produced in goats with
the exception of ICAM-1/CD54, E-selectin/CD62E and P-
selectin/CD62P that were produced in sheep. A list of all
antibodies can be found in Table S4.
Oligonucleotides
Oligonucleotides for conjugation to antibodies for purposes of
producing PLA probes were equipped with a thiol group at the
end to be attached to the antibody. PLA oligonucleotides with a 59
thiol modification were purchased from IDT while oligonucleo-
tides with a 39 thiol modification were obtained from Eurogentec.
All protein-specific and universal primers as well as the ligation
template were from IDT. The ligation template was designed to
allow specific ligation of all 36 oligonucleotide pairs. This was
achieved by designing the oligonucleotides on PLA probe pairs so
that each pair formed a nick at a unique position when hybridizing
to the ligation template. This sliding splint-mechanism served to
ensure that only cognate pairs of oligonucleotides, attached to
antibodies could be joined by ligation. The sliding splint concept is
described in greater detail in Figure S1. All oligonucleotides used
for library preparation prior to sequencing were from IDT. All
oligonucleotides were HPLC purified. For a complete list of all
oligonucleotides refer to Tables S5, S6, S7, S8.
Solid support preparation
The immobilization of biotinylated capture antibodies on
Dynabeads MyOne Streptavidin T1 (Invitrogen) paramagnetic
microparticles and the subsequent treatment and storage of the
beads was performed as described previously [19].
PLA probes preparation
Conjugation of oligonucleotides to antibodies was performed as
described by Soderberg et al. [29] with minor modifications. The
buffer used for the reduction of oligonucleotides was 1xPBS,
pH 7.4 containing 5 mM EDTA. Upon conjugation, the reactions
were purified in 96-well filter plates (MultiScreenHTS-HV Plate,
Millipore) to which 500 ml lllustra Sephadex
TM G-50 DNA Grade
resin (GE Healthcare) were added.
CVD sample set
The CVD sample set comprised three patient subgroups. For
each of the subgroups, sample collection was performed as follows:
Group 1: within 72 h after onset of unstable angina or minor
myocardial infarction (n=16); Group 2: upon arrival at the hospital
with sudden total thrombotic occlusion of a coronary artery as
evidenced by electrocardiographic ST segment elevation, moti-
vating reperfusion therapy (n=23); Group 3: in the emergency
department for patients with chest pain due to suspicion of
unstable coronary artery disease or myocardial infarction (n=24).
Samples were stored at 270uC until analyzed. The control
samples were collected from age- and gender-matched individuals
with no signs or symptoms of coronary disease (n=19). Descriptive
statistics of the patient and control groups can be found in Table
S9. All participants provided written informed consent and all
studies had ethical committee approvals as stated in the original
publications [30,31,32,33].
Solid-phase multiplex PLA
For each reaction we used 0.1 ml of microbeads modified by the
addition of the biotinylated capture antibody, corresponding to
0.75 ng of capture antibody, for every analyte in our multiplex
panel. After combining beads individually modified with antibod-
ies against all 36 analytes, the storage buffer was removed and
beads were re-suspended in PLA buffer (1 mM D-biotin (Invitro-
gen), 0.1% purified BSA (New England Biolabs), 0.05% Tween 20
Figure 3. a) Supervised multivariate classification. Typical results of a multivariate classifier design using 80% of the CVD samples. The cyan
(control) and magenta (patient) open circles indicate the positions of the training examples in the compressed three-dimensional meta-protein space,
created by the supervised procedure to classify the samples (see methods). The blue (controls) and red (patients) filled circles indicate the positions of
the external test examples used to evaluate the particular classifier designed. These examples were assigned to the most common class among the
three closest training examples (3-nearest neighbour classification). b) Supervised univariate analysis of individual proteins. Results obtained
from the CVD samples by a supervised univariate analysis of the individual proteins with respect to their discriminatory power when they were used
individually for 3-nearest neighbour classification. Each protein is displayed in terms of estimates of the probabilities of false alarm and miss that one
would obtain if an optimal cut-off level for that particular protein was used alone to distinguish patients and controls.
doi:10.1371/journal.pone.0025583.g003
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salmon sperm DNA (Invitrogen), 5 mM EDTA, PBS). We used
5 ml of the re-suspended bead mix in each reaction.
Recombinant proteins were serially diluted in PLA buffer in
concentrations ranging from 1 nM to 10 fM and with one
negative control to determine background noise.
Upon mixture of 5 ml bead mix and 45 ml of diluted
recombinant protein or ten-fold diluted plasma sample from
patients and controls, the reactions were incubated for 1.5 hours at
room temperature (RT) with constant rotation. This was followed
by two washes using wash buffer (PBS, 0.05% Tween 20) while the
reaction wells were positioned on a 96-well plate magnet (Perkin
Elmer Life Sciences).
After washes, 50 ml of PLA probe mix with each oligonucleo-
tide-conjugated antibody for a final concentration of 0.5 nM was
added to each reaction well. Reactions were incubated for 1.5 h at
RT with constant rotation, followed by two washes as described
above.
Next, 50 ml of ligation mix was added (1X AmpLigase buffer
(Epicentre biotechnology), 0.5 mM NAD (Sigma), 0.1 U AmpLi-
gase (Epicentre biotechnology), 100 nM ligation splint). After
10 min at 50uC, the beads were washed once.
Subsequently 50 ml of universal PCR mix (1X PCR buffer
(Invitrogen), 3 mM MgCl2 (Invitrogen), 100 nM universal forward
and reverse primers, 1.5 U Platinum Taq DNA polymerase
(Invitrogen), 0.2 mM dNTP mix (dATP, dGTP, dCTP, dUTP)
(Fermentas), 0.1 U uracil-N-glycosylase (Fermentas)) was added to
every well and pre-amplification was carried out using the
following thermocycling protocol, 10 min at 95uC, followed by
15 cycles of 15 sec at 95uC, 1 min at 62uC, and 1 min at 72uC.
Separate qPCRs were carried out for each ligation product in
384-well plates (Applied Biosystems) in which 2 ml of 0.5 mM
specific primer pairs for individual ligation products had been
previously added using a Hydra dispenser (Robbins Scientific).
Universally amplified products were diluted fifty-fold in PCR mix
and 8 ml were added to the primer-containing 384-well plates. The
qPCR thermocycling protocol included an initial incubation at
95uC for 2 min followed by 40 cycles of 15 sec at 90uC and 1 min
at 60uC.
Sandwich immunoassays
Aliquots of the same polyclonal antibodies used for PLA were
also coupled to Magnetic MAGPLEX microspheres (Luminex
Corporation; identities 7–9, 12–15, 18–22, 25–30, 33–39, 42–48,
65–68) according to the manufacturer’s recommended protocol.
For each assay we used 750–1000 beads suspended in 5 mlo f
assay buffer (1xPBS, 1% BSA). All blood samples were diluted ten-
fold in assay buffer prior to analysis for a final reaction volume of
each sample of 45 ml. Samples were incubated with the beads for
1.5 h in darkness with shaking at 650 rpm, followed by washing
with PBS-T (1xPBS, 0.05% Tween 20). Next, 50 ml of detection
solution was added to the beads, comprising all biotinylated
antibodies, each at a concentration of 3.33 nM. Upon washing,
50 ml of 0.5 mg/ml streptavidin-coupled R-phycoerythrin (Invitro-
gen Ltd) were added to the reaction and incubated for 30 min.
After removing the solution 125 ml PBS-T was added and the
reactions were transferred to a Luminex Lx200 instrument for
further analysis.
Library preparation for sequencing
ProteinSeq reactions were performed by adjusting the concen-
tration of certain PLA probes as shown in Table S3. This was
done to ensure that all resulting ligation products would be within
the same dynamic range of three orders of magnitude.
Universal PCR amplification was performed in 50 ml special
PCR buffer (50 mM KAc, 20 mM Tris-HAc, 3 mM MgAc2
pH 7.6), 100 nM universal forward and universal reverse primers,
1.5 U Platinum Taq DNA polymerase, 0.2 mM dNTP mix
(Fermentas), 0.1 U uracil-N-glycosylase (Fermentas)) with the
thermal profile described above and for 35 cycles.
Sample indexes were introduced by mixing 24 ml of each pre-
amplified reaction with 26 ml of indexing mix (0.5 mM PCR Index
forward and reverse primers, special PCR buffer with 1.5 U
Platinum Taq DNA polymerase and 0.2 mM dNTP mix
(Fermentas)) and incubating at 95uC for 10 min, 95uC for
15 sec, 62uC for 1 min and 72uC for 1 min.
Ten ml of each product were subsequently amplified with 40 ml
enrichment mix (Special PCR buffer, 0.5 mM enrich forward and
reverse primer, 1.5 U Platinum Taq DNA polymerase and
0.2 mM dNTP mix) by incubating at 95uC for 10 min and
subsequently performing 3 cycles of 95uC for 15 sec, 65uC for
30 sec and 72uC for 30 sec.
All reactions were purified in GFX
TM columns (GE Healthcare)
followed by size selection for 199 bp on 2% size-selection E-gel
(Invitrogen) using 50 bp DNA size ladder (Molecular Probes).
Selected products were quantified by qPCR and combined to 7
groups each containing 12 indexes prior to sequencing.
Sequencing
Sequencing was carried out using an Illumina Genome
Analyzer IIx sequencer. Pools of libraries were introduced into
the eight channels of a single-end flow cell. 95 bases of sequence
were prepared.
Sequencing data analysis
All reads were initially de-multiplexed by using the 6 bp sample
index sequence, allowing for a maximum of one mismatch. De-
multiplexed reads were then aligned to the reference sequence
using the GEM aligner to perform an exhaustive mapping
allowing for a maximum of five mismatches. Only uniquely
mapping reads were used for subsequent analyses, where a read
was declared unique with n mismatches if it did not match with less
than n mismatches, matched once with exactly n mismatches, and
did not match with n+1 mismatches.
The total number of reads obtained for every DNA molecule
that corresponded to each protein included in the ProteinSeq
panel was used for the analysis. Prior to analysis the absolute
number of sequencing reads was normalized against the internal
PLA control (mouse IgG). For a more detailed description of
sequencing statistics please refer to Figure S4.
Multivariate data analysis
All the multivariate data analysis was performed using in-house
code written in Matlab (Mathworks, USA) and code written in R
[34]. Codes are available upon request. For details regarding
missing values (imputation), the three different supervised learning
methods employed, the performed standardization of the protein
levels to a common scale and the careful performance estimation,
see Material S1.
Supporting Information
Figure S1 The concept of the sliding splint design. Each
multiplex SP-PLA oligonucleotide pair is ligated on the sliding
splint with a single nucleotide shift relative to the previous one. In
that way incorrect oligonucleotide combinations will not form
proper substrates for ligation and cannot be ligated.
(EPS)
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multiplex SP-PLA and sandwich immunoassay. The
LOD of multiplex SP-PLA and sandwich immunoassay for every
protein in the panel. The LOD is presented in
(EPS)
Figure S3 Library preparation for sequencing. Sample
barcodes are introduced in the pre-amplified ligation products by
polymerization. Subsequently, barcoded samples are mixed in one
tube prior to be sequenced. For more information please refer to
the Methods section.
(EPS)
Figure S4 Sequencing statistics. Columns indicate the
absolute number of reads for each category in the x-axis. The
number of reads of each category is also shown as a percentage of
the total number of reads.
(EPS)
Table S1 Conversion of molar concentrations to con-
centrations in pg/ml. The highest molar concentration (pM) for
every protein used in the cross-reactivity experiment is converted
to mass per volume concentration (pg/ml). In addition reaction
volumes are provided.
(DOCX)
Table S2 Detection limits for each protein included in
the panel. The limits of detection for each protein included in
the panel for both multiplex SP-PLA and sandwich immunoassays
are presented in pg/ml.
(DOCX)
Table S3 Adjusted concentration of each PLA probe.
Probe concentrations were adjusted in order to decrease PLA
reporting efficiency and thus limit the dynamic range of different
ligation products.
(DOCX)
Table S4 List of antibodies used as PLA probes.
(DOCX)
Table S5 Sequences of PLA arms. Sequences of all
oligonucleotides conjugated on antibodies by their 59, which was
modified by addition of a thiol group.
(DOCX)
Table S6 Sequences of PLA arms. Sequences of all
oligonucleotides conjugated on antibodies by their 39, which was
modified by addition of a thiol group.
(DOCX)
Table S7 PCR primer sequences. Sequences of all PCR
primers used in multiplex SP-PLA with qPCR readout.
(DOCX)
Table S8 Library preparation oligonucleotide sequenc-
es. Sequences of all oligonucleotides used for the preparation of
sequencing libraries.
(DOCX)
Table S9 Characteristics of patient and control groups.
(DOCX)
Material S1 Supplementary Material.
(DOCX)
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